1. Homepage
  2. Equities
  3. India
  4. Bombay Stock Exchange
  5. Hikal Limited
  6. Company
    524735   INE475B01022

HIKAL LIMITED

(524735)
  Report
End-of-day quote Bombay Stock Exchange  -  05-15
384.50 INR   -3.14%
04/23Hikal Limited Announces Closure of Manufacturing Unit Located at MIDC Taloja, Dist. Raigad, Within 15 Days
CI
02/23HIKAL LIMITED : Ex-dividend day for interim dividend
FA
02/18TRANSCRIPT : Hikal Limited, Q3 2022 Earnings Call, Feb 18, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Hikal Limited is engaged in the manufacturing of various chemical intermediates, specialty chemicals, active pharma, ingredients, and contract research activities. The Company’s operating segments include the crop protection and pharmaceuticals space. The Crop protection produce and trades in pesticides and herbicides. Its facilities are in Taloja, Mahad (Maharashtra), and Panoli (Gujarat). The Pharmaceuticals space produce and trades in active pharmaceuticals ingredients. Its facilities are in Jigani (Bengaluru) and Panoli (Gujarat). The Company’s products and services include gabapentin, thiabendazole, and diuron contract development and custom manufacturing of intermediates, application programming interface (APIs), and artificial intelligence (AI’s). It offers solutions to route scouting, process development, analytical method development, technology development, process engineering, scale-up support, and small-scale synthesis.

Number of employees : 2 308 people.
Sales per Business
20202021Delta
Pharmaceuticals8 868.7158.8%10 596.4061.6% +19.48%
Crop Protection6 203.9241.2%6 607.9638.4% +6.51%
INR in Million
Sales per region
20202021Delta
South East Asia4 386.2429.1%5 466.5531.8% +24.63%
India3 983.5426.4%5 381.7331.3% +35.1%
Europe4 402.9229.2%3 764.5421.9% -14.5%
United States and Canada2 101.2013.9%2 063.3612% -1.8%
Others198.731.3%528.183.1% +165.78%
INR in Million
Managers
Name Title Age Since
Sameer Jai Hiremath Managing Director & Director 47 2021
Kuldeep Jain Chief Financial Officer - 2020
Rajasekhar Reddy Secretary & Compliance Officer - 2020
Anish Swadi President-Strategy & Business Development - 2005
Kumar Inamdar President-Crop Protection - -
Kumaar Priyaranjan President-Human Capital & CSR - -
Members of the board
Name Title Age Since
Jai Vishwanath Hiremath Executive Chairman 73 2021
Kannan Kadankote Unni Independent Non-Executive Director 78 2011
Prakash Vasantlal Mehta Independent Non-Executive Director 80 2011
Ranjit G. Shahani Independent Non-Executive Director 71 2018
Sachdeva Shivani Bhasin Independent Director - 2019
Shrikrishna Kiran Adivarekar Independent Director 39 2021
Sameer Jai Hiremath Managing Director & Director 47 2021
Sugandha Jai Hiremath Non-Executive Director 69 1992
Babasaheb Neelkanth Kalyani Non-Independent Non-Executive Director 73 2012
Amit Babasaheb Kalyani Non-Independent Non-Executive Director 46 2010
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 123,272,470 38,244,139 31.0% 0 0.0% 31.0%
Shareholders
NameEquities%
Kalyani Investment Company Limited 38,667,375 31.4%
Shri Badrinath Investment Pvt Ltd. 19,914,862 16.2%
Shri Rameshwara Investment Ltd. 9,810,000 7.96%
Sugandha Jai Hiremath 9,667,500 7.84%
Capital Research & Management Co. (World Investors) 4,342,326 3.52%
BF Investment Limited 3,273,375 2.65%
Norges Bank Investment Management 2,400,000 1.95%
Jai Vishwanath Hiremath 1,340,625 1.09%
Dimensional Fund Advisors LP 938,464 0.76%
Ekdant Investments Pvt Ltd. 393,802 0.32%
Company contact information
Hikal Ltd.
Great Eastern Chambers, 6 Floor
Sector 11, Navi Mumbai
C. B. D. Belapur
Mumbai, Maharashtra 400614

Phone : +91.22.30973100
Fax : +91.22.27574277
Web : http://www.hikal.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Hikal Limited
Sector Other Pharmaceuticals
1st jan.Capi. (M$)
HIKAL LIMITED-27.00%609
JOHNSON & JOHNSON4.10%468 600
PFIZER, INC.-14.19%284 304
ABBVIE INC.14.82%274 733
ELI LILLY AND COMPANY8.38%269 490
ROCHE HOLDING AG-14.96%260 807
MERCK & CO., INC.20.46%233 459
NOVO NORDISK A/S0.00%233 430
ASTRAZENECA PLC20.60%198 605
NOVARTIS AG9.03%192 913
BRISTOL-MYERS SQUIBB COMPANY23.35%163 746
AMGEN INC.8.40%130 275
SANOFI12.89%129 906
GLAXOSMITHKLINE PLC11.94%111 472
BAYER AG34.49%64 606
DAIICHI SANKYO CO., LTD.14.22%49 597
CHUGAI PHARMACEUTICAL CO., LTD-4.52%45 417
TAKEDA PHARMACEUTICAL COMPANY LIMITED16.70%43 765
JIANGSU HENGRUI MEDICINE CO., LTD.-41.96%27 671
ASTELLAS PHARMA INC.4.57%27 283
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD-31.52%26 620